Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Anti-Angiogenesis Effects Induced by Octaminomycins A and B against HUVECs

  • Jang, Jun-Pil (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology) ;
  • Han, Jang Mi (Department of Pharmaceutical Engineering and Biotechnology, Sun Moon University) ;
  • Jung, Hye Jin (Department of Pharmaceutical Engineering and Biotechnology, Sun Moon University) ;
  • Osada, Hiroyuki (Chemical Biology Research Group, RIKEN Center for Sustainable Research Science) ;
  • Jang, Jae-Hyuk (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology) ;
  • Ahn, Jong Seog (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology)
  • Received : 2018.06.21
  • Accepted : 2018.06.26
  • Published : 2018.08.28
Download PDF
⟨ Previous Next ⟩

Abstract

In the course of studies to discover natural products with anti-angiogenic properties, two cyclic octapeptides, octaminomycins A (1) and B (2), were isolated from the cultures of Streptomyces sp. RK85-270. Octaminomycins suppressed the vascular endothelial growth factor (VEGF)-induced proliferation, adhesion, tube formation, migration, and invasion of HUVECs. Anti-angiogenic activity was futher confirmed in vivo by the chicken chorioallantoic membrane assay. We also identified that 1 and 2 inhibited the phosphorylation of VEGF receptor 2, AKT, and ERK1/2 and the expression and activities of MMP-2 and MMP-9. These results suggest that 1 and 2 may serve as potential scaffolds for the development of therapeutic agents to angiogenesis-dependent diseases.

Keywords

References

  1. Ne wman DJ, Cragg GM. 2016. Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod. 79: 629-661. https://doi.org/10.1021/acs.jnatprod.5b01055
  2. Cragg GM, Newman DJ. 2013. Natural products: a continuing source of novel drug leads. Biochim. Biophys. Acta 1830: 3670-3695. https://doi.org/10.1016/j.bbagen.2013.02.008
  3. Clardy J, Fischbach MA, Walsh CT. 2006. New antibiotics from bacterial natural products. Nat. Biotechnol. 24: 1541-1550. https://doi.org/10.1038/nbt1266
  4. Genilloud O, Gonzalez I, Salazar O, Martin J, Tormo JR, Vicente F. 2011. Current approaches to exploit actinomycetes as a source of novel natural products. J. Ind. Microbiol. Biotechnol. 38: 375-359. https://doi.org/10.1007/s10295-010-0882-7
  5. Nett M, Ikeda H, Moore BS. 2009. Genomic basis for natural product biosynthetic diversity in the actinomycetes. Nat. Prod. Rep. 26: 1362-1384. https://doi.org/10.1039/b817069j
  6. Kerbel R, Folkman J. 2002. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2: 727-739. https://doi.org/10.1038/nrc905
  7. Jubb AM, Oates AJ, Holden S, Koeppen H. 2006. Predicting benefit from anti-angiogenic agents in malignancy. Nat. Rev. Cancer 6: 626-635. https://doi.org/10.1038/nrc1946
  8. Carmeliet P. 2005. VEGF as a key mediator of angiogenesis in cancer. Oncology 69: 4-10. https://doi.org/10.1159/000088478
  9. Ferrara N. 2004. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9: 2-10. https://doi.org/10.1634/theoncologist.9-suppl_1-2
  10. Ferrara N, Davis-Smyth T. 1997. The biology of vascular endothelial growth factor. Endocr. Rev. 18: 4-25. https://doi.org/10.1210/edrv.18.1.0287
  11. Berqurs G, Hanahan D. 2008. Modes of resistance to antiangiogenic therapy. Nat. Rev. Cancer 8: 592-603. https://doi.org/10.1038/nrc2442
  12. Jang JP, Nogawa T, Futamura Y, Shimizu T, Hashizume D, Takahashi S, et al. 2017. Octaminomycins A and B, cyclic octadepsipeptides active against Plasmodium falciparum. J. Nat. Prod. 27: 134.
  13. Staton CA, Reed MW, Brown NJ. 2009. Acritical analysis of current in vitro and in vivo angiogenesis assays. Int. J. Exp. Pathol. 90: 195-221. https://doi.org/10.1111/j.1365-2613.2008.00633.x
  14. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. 2004. Vascular endothelial growth factor and angiogenesis. Pharmacol. Rev. 56: 549-580. https://doi.org/10.1124/pr.56.4.3
  15. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. 2006. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell. Biol. 7: 359-371. https://doi.org/10.1038/nrm1911
  16. Hass TL. 2005. Endothelial cell regulation of matrix metalloproteinases. Can. J. Physiol. Pharmacol. 83: 1-7. https://doi.org/10.1139/y04-120

Cited by

  1. Heterologous Expression of Daptomycin Biosynthetic Gene Cluster Via Streptomyces Artificial Chromosome Vector System vol.29, pp.12, 2018, https://doi.org/10.4014/jmb.1909.09022
  2. Antiangiogenic effect of pinobanksin on human umbilical vein endothelial cells vol.79, pp.None, 2018, https://doi.org/10.1016/j.jff.2021.104408